Member Info for Fanti

@ Glenfriedrich

Dr Parker meanwhile had a rethink about his statement meanwhile.

I ackknowledge SAR is challenged by our promising assets and its progress but even worse financially also. IMHO, the BODs financing strategy can neither be short term managed year by year nor simply focus on the trials while there is no revenue and cash available to simply pay the employees temporarily on its own. Don't they see the going concern principle basically is on the cards?

I guess SRA 737 cannot be shelfed any much longer and better is sold for good to any interested party when buying the 50% stake was no option.

Science is fine yet finances are a concern, I agree.

Since our revenue and thus our financial situation depends on the CPF solely I wonder if it was possibly an option to buy in and increase our interest up to 50% plus's in SRA737 simply to actively control and market and commercialise the asset.

Has one get an idea what it is worth and expenditure was like?

I think RF behaves well so far. No death spiralling and shorters in sight.

https://shortsell.nl/short/Sareum/all

Given the loss of 3,2 and the trial imminent financing was overdue Id say.

On a positive note, RF do trust the science and will sit on a substantial holding in a not so distant future.

Not sure what risk potential is, though.

Germany signalling pressure. We should answer the call.

I have placed three orders meanwhile. The German stockexchange is not participating at all!

Condolenses also from my side. T2 was an astonishing knowlegeable man with a good sense of good and sharp humour. Sadly missed and a shame he passed away that early.

?This Monday's RND delivers a great comprehension about SRA737 and is way of promotion on our behalf. Well done. Since the return is official now any interested party is invited to come forward in approaching CPF and any query already put behind the scene, if any, shall being considered finally.
I may be wrong but CPF probably is most likely to mention the return in a monthly newsletter only.

The SRA737 patents were not granted at the time when the decision was mate on behalf of Momelotinib. As they are not now.

https://patents.google.com/patent/EP3609884A1/en

I wonder if these circumstances have an impact on the assets return.

Well, I now see. My apologies. My english is poor indeed but God thanks there we have Google translator for helping me out. Eventually :).

Scheckler is right. $6 Bn. Agreed.

Takeda has now acquired TAK-279, formerly known at Nimbus as NDI-034858.
Calculation goes like: 4+1+1 +5= 11

Thanks for clarification when I do get this wrong.

Hi there, are you guys kidding me? Article is great source in detail hence the reference.
Once you are willing to add on $5Bn on top for further developments then you come close to $10 Bn for the deal.

Speaking of $11 Bn as a matter of fact, though, for the Ph 2b compound, recruiting atm.

...
Under the terms of the agreement and following the closing of the transaction, Takeda will pay Nimbus approximately 4 billion USD upfront, after adjusting items including closing indebtedness and closing account payable of Lakshmi. Takeda will also make two milestone payments to Nimbus of 1 billion USD each upon achieving annual net sales of 4 billion USD and 5 billion USD of products developed from the TAK-279 program.
...

Just to double check $10 Bn here:

https://www.takeda.com/newsroom/newsreleases/2023/takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary

BMS sees potential for Sotyktu (Psoriasis) as much as $4 billion in annual sales by 2030.
In less than a full month of sales, article says, the drug pulled in $1 million in revenue.

Article suggests to eventually start thinking big in numbers.
GLA

https://www.theglobeandmail.com/investing/markets/stocks/BMY-N/pressreleases/13904069/will-these-3-potential-blockbuster-drugs-lift-bristol-myers-squibb/

Sorry, if already posted.

Of course, BEST is just wishful thinking. Dizzingly high numbers most likely unreal.

It's embarrassing how little attention is paid to what is being said. Cheers Ahfam, compilation of statements is nice and promising.

FC 2023: BEST $5,5Bn. :)

Silly me, CTA Application of SDC-1801 in pre clinical stage worth half $5 Bn comes to mind. LoL

worth up to $10 Bn.?! NDI-034858 a phase 2 drug.

https://www.takeda.com/newsroom/newsreleases/2023/takeda-completes-acquisition-of-nimbus-therapeutics-tyk2-program-subsidiary

Re the application outside UK, I wonder if residency or a representative was crucial to being formally entitled for an application. Anyway. Sooner or later we will find out.

My writing to be understood precautional in case of a rejection. Just don't want to loose even more on value as we already have, since we were badly beaten down lately. Remember?
CTA approval might be key to any kind of progression and was even better to have but intention also or simply is to on licence and for sale. When I get this right.